Genomics of Ochrobactrum pseudogrignonense (newly named Brucella pseudogrignonensis) reveals a new bla\textsubscript{OXA} subgroup

Shu-Yuan Li\textsuperscript{1}, Yin-En Huang\textsuperscript{2}, Jhih-Yang Chen\textsuperscript{2}, Chung-Hsu Lai\textsuperscript{1,3,4}, Yan-Chiao Mao\textsuperscript{5,6}, Yao-Ting Huang\textsuperscript{2,*} and Po-Yu Liu\textsuperscript{1,7,8,*}

Abstract

Ochrobactrum pseudogrignonense (newly named Brucella pseudogrignonensis) is an emerging pathogen in immunodeficient and immunocompetent patients. Most documented cases associated with Ochrobactrum are frequently catheter-related and exhibit wide-spectrum \(\beta\)-lactam resistance. Misidentification of this pathogen using commercial bacterial identification kits is common. We identified a case of \(O.\) pseudogrignonense infection associated with cholelithiasis. The \(O.\) pseudogrignonense genome was sequenced and reconstructed using a Nanopore and Illumina hybrid strategy. A novel \(\text{bla}_{\text{OXA-919}}\) divergent from existing OXA members was identified and subsequent analysis revealed its existence in all available \(O.\) pseudogrignonense genomes, which forms a new phylogenetic subgroup distinct from other OXA clusters. Further analysis demonstrated the presence of the novel \(\text{bla}_{\text{OXA-919}}\) in the chromosome of several other \(Ochrobactrum\) species. Our study indicated that \(Ochrobactrum\) chromosomes may be a reservoir of \(\text{bla}_{\text{OXA-919}}\) \(\beta\)-lactamases.

DATA SUMMARY

All the sequencing data have been deposited in GenBank under BioProject ID no. PRJNA505957 accession PKQI00000000. (https://www.ncbi.nlm.nih.gov/nuccore/PKQI00000000.1/). All the supporting data have been provided through supplementary data files.

INTRODUCTION

Ochrobactrum has been recognized as an emerging pathogen in immunodeficient and immunocompetent patients. Recently, the genus Ochrobactrum was renamed within Brucella. However, the clinical characteristics are different between the two groups. To date, Ochrobactrum anthropi (newly named \(B.\) anthrophi), \(O.\) intermedium (\(B.\) intermedium), \(O.\) tritici (\(B.\) tritici), \(O.\) haemophilum (\(B.\) haemophilum) and \(O.\) pseudogrignonense (\(B.\) pseudogrignonensis) have been reported to cause human infections [1]. Most Ochrobactrum infections are catheter-related, such as central venous vein catheters, drainage tubes and intraperitoneal catheters, because of the ability of the pathogen to adhere to silicone [1]. Ochrobactrum species show wide-spectrum \(\beta\)-lactam resistance. Previous studies reported that \(\beta\)-lactam resistance is associated with production of an inducible chromosomally encoded Amp-C \(\beta\)-lactamase [2]. Misidentification of Ochrobactrum species using commercial bacterial identification kits is common and leads to diagnostic difficulties in clinical settings [1].

\(O.\) pseudogrignonense is a gram-negative, non-motile, non-spore-forming and oxidase-positive rod-shaped bacterium [3]. It is a naturally occurring environmental organism found in water and soil [4]. It has been shown to be a pathogen of a fungus [5]. Whole genome sequencing of \(O.\) pseudogrignonense was reported in 2016 from Malaysian tropical soil. Clinical cases were reported in Sweden in 1992 and in Norway in 2000, respectively, from blood of a 28-year-old patient and the ear of a newborn [3]. Recently, a human case report in Korea
described bacteraemia in a 44-year-old man with extracorporeal membrane oxygenation [6].

In this study, we report the genomic analysis of a clinical O. pseudogrignonense isolate in Taiwan and conduct comparative genomics with publicly available genomes of O. pseudogrignonense (K8, MYb58, CCUG 30717, CCUG43892, MYb37, MYb70 and CIP 109451).

METHODS

Sample description

An 86-year-old male patient presented with fever and abdominal pain. He had a background of hypertension, history of liver abscess, benign prostatic hyperplasia and pulmonary tuberculosis (for which he received complete treatment at age of 20 years). He received percutaneous transhepatic gallbladder drainage under the impression of gallstone-related acute cholecystitis. After drainage, fever improved. Liver sonography showed bilateral intrahepatic duct dilatation. T-tube cholangiography revealed an obstructive cystic duct. He was referred to a general surgeon and was admitted to the ward for laparoscopic cholecystectomy.

On the first day of hospitalization, he was afebrile, with blood pressure 133/71 mmHg and heart rate 72 b.p.m. Laboratory findings indicated a white blood cell count of 6700 μl⁻¹ with a differential of 60% neutrophils, a haemoglobin level of 11.5 g dl⁻¹, a platelet count of 183×10³ μl⁻¹, total bilirubin of 0.3 mg dl⁻¹, direct bilirubin of 0.1 mg dl⁻¹, AST (aspartate aminotransferase) of 18 U l⁻¹ and ALT (alanine aminotransferase) of 8 U l⁻¹. He received laparoscopic cholecystectomy on admission day 2. Intravenous antibiotics with cefazolin (1000 mg every 8 h) was started on the day of operation. Operative findings showed gallbladder about 6×13 cm in size with multiple pigmented stones inside and a cystic duct diameter of about 0.84 cm. Bile leakage was observed during the operation, so he received wound care with subsequent wet dressing. The wound was closed on postoperative day 2. Brown colour drainage was observed on postoperative day 3. Because bile leakage was suspected, he received

Fig. 1. Circular maps of two chromosomes and three plasmids of O. pseudogrignonense (newly named B. pseudogrignonense) SHIN. The novel \( \text{bla}^{\text{OXA-919}} \) is on chromosome 1, \( \text{bla}^{\text{Imp-8}} \) is on plasmid 2 and ampC is on chromosome 2.
endoscopic retrograde biliary drainage on post-operative day 5. Surgical pathology showed cholelithiasis and chronic active cholecystitis. On post-operative day 5, bile culture yielded morphologically homogeneous colonies which were preliminarily identified as *O. anthropi* by MALDI-TOF. He received intravenous tigecycline (100 mg loading dose, maintenance dose 50 mg every 12 h) for 7 days and was discharged on day 14. He received biliary drainage removal 2 months after discharge without specific complications.

Whole genome sequencing of the isolate and computation of whole-genome average nucleotide identity (ANI) against other species in the same genus was performed. The results indicated 98.99% ANI with *O. pseudogrignonense* CCUG 30717. Antimicrobial susceptibility testing showed that the isolate was sensitive to imipenem, colistin, tigecycline, amikacin and trimethoprim-sulfamethoxazole, but resistant to gentamicin, ampicillin-sulbactam, ceftazidime, cefepime, ceftriaxone, ciprofloxacin and piperacillin-tazobactam.

**Genome sequencing, assembly and annotation**

The *O. pseudogrignonense* SHIN genome was deeply sequenced using Nanopore long-read sequencing at 123× and Illumina short-read sequencing at 56×. Adaptor sequences left in long reads were trimmed using Porechop. The remaining reads were hybrid-assembled via Unicycler (v0.4.7) (N50=1880620 bp), and classified into two chromosomes and three plasmids. Protein-coding genes, and coding and non-coding RNAs in the chromosomes and plasmids were annotated via the NCBI PGAP pipeline. Antibiotic-resistant genes (ARGs) were predicted by aligning protein-coding genes against the Comprehensive Antibiotic Resistance Database (CARD) using Diamond. Only ARGs with alignment coverage greater than 90% were retained. Efflux pumps were excluded from ARG analysis.

**Motif and phylogenetic analysis of OXA family members**

Multiple sequence alignment of OXA-919 and other OXA members was carried out by **mega x** to identity the conserved motifs. The alignment was used for generating a phylogeny tree by **mega x**, which was visualized by **ITOL** in order to construct a circular phylogeny tree.

**Data deposition**

This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank under accession PKQI00000000. The version described in this paper is version PKQI00000000.1.
β-lactams, including penicillin, cephalosporins and carbapenems (Table S3). Analysis of the SHIN resistome indicates the presence of 148 ARGs, including three β-lactamases in distinct classes (Table S4). In particular, one novel class D β-lactamase (called bla\textsubscript{OXA-919}) is found on chromosome 1. There are no associated mobile genetic elements or integrative and conjugative elements found around bla\textsubscript{OXA-919}. A class C β-lactamase (ampC) is present on chromosome 2. A class B metallo-beta-lactamase, bla\textsubscript{Imp-8}, is carried by plasmid 2 (Fig. S1). These chromosomal-encoding β-lactamases along with plasmid-encoding carbapenemase are probably the major resistance factors to a wide spectrum of β-lactams.

The novel class D bla\textsubscript{OXA-919} beta lactamase is harboured by all \textit{O. pseudogrignonense}

The class C β-lactamase, ampC, is well known in \textit{Ochrobactrum} genomes and also encoded in chromosome 2 of the SHIN genome. To the best of our knowledge, this is the first report of the presence of class D β-lactamases (OXA) in \textit{Ochrobactrum} (designated as NG\_070746.1/WP\_007879679.1 by NCBI). By comparing bla\textsubscript{OXA-919} with known OXA members, we found that it is quite dissimilar from others (e.g. AAI=40.16% to OXA-45 and AAI=27.52% to OXA-54). Nevertheless, bla\textsubscript{OXA-919} contains classic OXA signatures of three highly conserved motifs, S-T-F-K, Y-G-N and K-T-G, although the sequence outside the motifs diverges (Fig. 2), implying it is possibly a novel member in the current OXA family. We then used a BLAST search for the presence of bla\textsubscript{OXA-919} in other public \textit{O. pseudogrignonense} genomes in NCBI (Table S5) and found all of them carry bla\textsubscript{OXA-919} (Table S5). By searching the NCBI protein database, bla\textsubscript{OXA-919} (WP\_007879679.1) is 100% identical to one annotated protein (AKVI01000111.1/EMG52215.1) in the \textit{Ochrobactrum} sp. CDB genome. This indicated that, in addition to ampC, bla\textsubscript{OXA-919} is another common β-lactamase encoded under the genus \textit{Ochrobactrum}. Consequently, \textit{Ochrobactrum} is probably the reservoir of class C and class D β-lactamases. Unfortunately, the resistance profiles of these public \textit{Ochrobactrum} genomes are not available. Therefore, we investigated the resistance phenotypes of 13 additional \textit{Ochrobactrum} samples.

\textbf{Fig. 3.} Circular phylogeny of ten OXA groups. The novel bla\textsubscript{OXA-919} allele is clustered with other highly similar members (> 98.5% AAI) within \textit{B. pseudogrignonense} (formerly \textit{O. pseudogrignonense}). These bla\textsubscript{OXA-919} alleles form a new subgroup between the OXA-1 and OXA-48 groups.
| Case no. (Ref.) | Age (years)/sex | Underlying conditions | Clinical presentation | Indwelling catheter/procedure | Specimens | Identification methods | Reported pathogens | Antimicrobial therapy | Outcome |
|----------------|-----------------|-----------------------|----------------------|-------------------------------|-----------|-----------------------|--------------------|---------------------|---------|
| 1 (our case)   | 86/M            | HTN, liver abscess, TB | Acute cholecystitis  | Biliary drainage tube         | Bile      | Whole genome sequencing | O. pseudogrignonense (newly named B. pseudogrignonense) | TGC     | Recovered            |
| 2 [36]         | 70/M            | CCC                   | Bacteremia, cholecystitis | Biliary drainage tube         | Bile, blood | 16S rRNA partial sequencing | O. tritici | CPZ/SUL | Recovered            |
| 3 [18]         | 62/M            | Pancreatic cancer     | Biliary sepsis       | No                            | Blood     | Vitek II             | O. anthropi       | ERP     | Recovered            |
| 4 [18]         | 60/M            | CCC                   | Biliary sepsis       | Biliary drainage tube         | Bile, blood | Vitek II             | O. anthropi       | IMP     | Recovered            |
| 5 [18]         | 70/M            | CCC                   | Bacteremia, cholecystitis | Biliary drainage tube         | Bile      | Vitek II             | O. anthropi       | IMP     | Recovered            |
| 6 [18]         | 57/M            | CCC                   | Biliary sepsis       | Biliary drainage tube         | Bile, blood | Vitek II             | O. anthropi       | IMP     | Recovered            |
| 7 [18]         | 57/M            | HCC                   | Biliary sepsis       | Biliary drainage tube         | Blood     | Vitek II             | O. anthropi       | IMP     | Recovered            |
| 8 [18]         | 69/M            | CCC                   | Biliary sepsis       | Biliary drainage tube         | Bile, blood | Vitek II             | O. anthropi       | CIP     | Recovered            |
| 9 [18]         | 67/M            | CCC                   | Biliary sepsis       | Biliary drainage tube         | Blood     | Vitek II             | O. anthropi       | CIP     | Recovered            |
| 10 [18]        | 58/F            | HCC                   | Biliary sepsis       | No                            | Blood     | Vitek II             | O. anthropi       | CTX†    | Recovered            |
| 11 [18]        | 62/M            | Cirrhosis             | SBP                  | No                            | Blood, ascites | Vitek II             | O. anthropi       | IMP     | Died†                |
| 12 [25]        | 26/M            | None                  | Non-ulcer dyspepsia  | No                            | Antral biopsy | 16S rRNA+RecA gene sequencing | O. intermedium | (−)       | (−)                 |
| 13 [37]        | 74/M            | Bladder cancer        | Bacteremia           | Elective exploratory laparotomy, coelostomy | Blood, stool | 16S  rDNA sequencing+phenotype test§ | O. intermedium | IMP +CIP | Recovered            |
| 14 [24]        | 45/F            | PSC with Child-Pugh A cirrhosis | Cholangitis, liver abscess | Orthotopic liver transplantation+Roux-en-Y hepaticojunostomy | Blood, stool (before and during bacteremia), abscess culture (OP) | 16S rDNA primers followed by DNA sequence analysis | O. intermedium | IMP+CIP re-transplant | Recovered |
| 15 [38]        | 61/F            | HTN, CKD, MI, old CVA, gallstone pancreatitis post-cholecystectomy | Cholangitis after ERCP | ERCP and T tube | T tube, blood culture | Unknown | O. anthropi | GEM+IMP +TMP/SMZ+CAZ | Died|| |
| 16 [22]        | 75/M            | Chronic lung disease, HTN, MI, stroke | Pancreatic abscess, gastric outlet obstruction | Laparotomy+external pancreatic drainage+side to side gastro-jejunostomy | Pancreas abscess (OP) | Unknown | O. anthropi | GEM | Died¶ |

*Vitek II (bioMérieux).
†Non-susceptible antibiotic.
‡Due to gastrointestinal bleeding.
§Phenotype test: resistance to both colistin/polymyxin B.
||Due to progressive liver failure.
††Due to aspiration.
**HTN, hypertension; TB, tuberculosis; CCC, cholangiocarcinoma; HCC, hepatocellular carcinoma; CKD, chronic kidney disease; MI, myocardial infarction; CVA, cerebrovascular accident; SBP, spontaneous bacterial peritonitis; PSC, primary sclerosing cholangitis; ERCP, endoscopic retrograde cholangiopancreatography.
¶¶Ciprofloxacin; CTX, cefotaxime; MTZ, metronidazole; GEN, gentamicin; TMP/SMZ, trimethoprim/sulfamethoxazole; CAZ, ceftazidime.
collected in our hospital (Table S6), including nine *O. anthropi* and four *O. intermedium*. All of these additional samples exhibited strong resistance to penicillin, and first- and third-generation cephalosporins.

**bla**<sub>OXA-919</sub> **forms a new cluster within the OXA phylogeny**

Phylogenetic analysis of **bla**<sub>OXA-919</sub> sequences from the seven *O. pseudogrignonense* genomes with existing nine-group OXA members revealed a new group (called **bla**<sub>OXA-919</sub> group) (Fig. 3). The **bla**<sub>OXA-919</sub> alleles from *O. pseudogrignonense* are highly similar to each other (> 98.5% AAI) (Fig. S2). The resulting **bla**<sub>OXA-919</sub> group falls between the OXA-1 and OXA-48 groups, implying an OXA cluster is missing from the existing phylogeny. Comparison of the GC content of an OXA gene with that of the whole genome provides clues to the origin of the gene because their GC contents are likely to be similar. The GC content of **bla**<sub>OXA-919</sub> is 52.66% in the SHIN genome, which is similar to that of whole genomes of *O. pseudogrignonense* (53.6–54.32%) (Table S7). The GC content of **bla**<sub>OXA-919</sub> is also quite different from other OXA members (e.g. 37.5% in OXA-23), suggesting that **bla**<sub>OXA-919</sub> may have existed in *O. pseudogrignonense* for a long period of time. Analysis of OXA-919 of 17 *Ochrobactrum* species indicated that OXA-919 is also found in several species (e.g.

### Table 2. Identification issues in clinical reports of *Ochrobactrum* infection

| Case no. (Ref.) | Methods for initial identification | Initial identification | Methods for re-identification | Revised identification |
|-----------------|-----------------------------------|------------------------|-------------------------------|------------------------|
| 1 (our case)    | Vitek 2                           | *Ochrobactrum anthropi*| Whole genome sequencing       | *Ochrobactrum pseudogrignonense* (newly named *Brucella pseudogrignonense*) |
| 2 [36]          | MALDI-TOF MS                      | *Ochrobactrum anthropi*| 16S rRNA partial sequencing   | *Ochrobactrum tritici*  |
| 13 [37]         | Vitek                             | *Ochrobactrum anthropi*| 16S rDNA sequencing-resistance to both colistin/polymyxin B | *Ochrobactrum intermedium* |
| 14 [24]         | API 20 NE system                   | *Ochrobactrum anthropi*| 16S rDNA primers followed by DNA sequence analysis | *Ochrobactrum intermedium* |

### Table 3. Antimicrobial susceptibility profiles in clinical reports of *Ochrobactrum* infections

| Case no. (Ref.) | AMP/SUL | PIP/TAZO | CRO | CAZ | FEP | CIP | GEM | AMK | TMP/SMZ | CR | TGC |
|-----------------|---------|----------|-----|-----|-----|-----|-----|-----|---------|----|-----|
| 1 (our case)    | R       | R        | R   | R   | R   | R   | S   | S   | S       | S  | S   |
| 2 [36]          | R       | R        |     |     |     |     |     |     |         |    |     |
| 3 [18]          | R       | R        | R   | R   | S   | I   | R   | S   | S       |    |     |
| 4 [18]          | R       | I        | R   | I   | S   | S   | S   | S   | S       |    |     |
| 5 [18]          | R       | I        | R   | R   | S   | I   | I   | S   | S       |    |     |
| 6 [18]          | R       | R        | R   | R   | S   | I   | I   | S   | S       |    |     |
| 7 [18]          | R       | R        | R   | R   | S   | S   | S   | S   | S       |    |     |
| 8 [18]          | R       | R        | R   | R   | S   | S   | S   | S   | S       |    |     |
| 9 [18]          | R       | R        | R   | R   | S   | S   | S   | S   | S       |    |     |
| 10 [18]         | R       | R        | R   | R   | S   | S   | S   | S   | S       |    |     |
| 11 [18]         | R       | R        | R   | R   | S   | S   | S   | S   | S       |    |     |
| 12 [25]         | S       | R        | R   | S   | R   | S   | R   | S†  |         |    |     |
| 13 [37]         | S       | S        |     |     |     |     |     |     |         |    |     |
| 14 [24]         | R (>256)| S (0.19) |     |     |     |     |     |     |         |    |     |
| 15 [38]         |         | No data available |     |     |     |     |     |     |         |    |     |
| 22              |         | S        | R   | S   |     |     |     |     |         |    |     |

*Test tetracycline.
†Blood 0.094 µg ml⁻¹, liver/faeces 0.125 µg ml⁻¹.
‡Imipenem, blood 1.5 µg ml⁻¹, liver/faeces 1.0 µg ml⁻¹.
§AMP/SUL, ampicillin/sulbactam; PIP/TAZO, piperacillin/tazobactam; CRO, ceftiraxone; CAZ, ceftazidime; FEP, cefepime; CIP, ciprofloxacin; GEM, gentamicin; AMK, amikacin; TMP/SMZ, trimethoprim/sulfamethoxazole; CR, carbapenem; TGC, tigecycline.
DISCUSSION

Ochrobactrum species are emerging pathogens in immunodeficient and immunocompetent patients [7]. We report the first case of O. pseudogrignonense infection and whole genome sequencing in Taiwan.

Ochrobactrum infections are associated with catheters or direct contamination of wounds [8–10], intravenous fluid [4], grafts [11] and medical devices [12, 13] by the pathogen. Case reports of infections related to Ochrobactrum species have included endocarditis [14–16], meningitis [11], brain abscess [8], peritonitis [17, 18], endophthalmitis [12, 19], osteomyelitis [10], prostatitis [13], septic arthritis [9], urosepsis [20], soft tissue infection [21], pancreatic abscess [22] and pneumonia [23].

A literature review revealed 15 studies associated with biliary tract or gastrointestinal tract infection caused by Ochrobactrum species. The isolated pathogen included Ochrobactrum tritici, O. anthropi and O. intermedium (Table 1). Most cases had underlying chronic illness or malignancy and the patient received a procedure during admission (biliary drainage, operation, post-operative drainage tube and endoscopic retrograde cholangiopancreatography) before infection episodes. A pathogen from the environment and adhering to the catheter may be the possible source of infection, similar to most previous case reports. Three cases [18] reported biliary sepsis and spontaneous bacterial peritonitis (SBP) without a drainage tube, demonstrating the possibility of Ochrobactrum species originating from the human gastrointestinal tract or biliary tract. Isolated culture from stool before bacteraemia [24] and antral biopsy [25] supported a possible source from the gastrointestinal tract. Ochrobactrum has been proposed as a component of the normal human intestinal flora and pathogen of a fungus tumour in the literature. Bacterial translocation from the gastrointestinal tract or acquisition from the mouth may be the possible route of pathogenesis of Ochrobactrum infections. Most cases recovered from Ochrobactrum infection, even under inappropriate empirical antibiotics, support the low pathogenicity of Ochrobactrum species.

Misidentification of the pathogen using commercial bacterial identification kits also occurred in our case and the literature (Table 2). Vaidya et al. [26] reported that a case of pelvic abscess due to O. intermedium was incorrectly identified as O. anthropi by API 20NE and 16S RNA gene sequencing analysis. Misidentification of Brucella species as O. anthropi using MALDI-TOF MS and the VITEK 2 system was also reported previously [27, 28]. Teysseyer et al. [7], who tested the ability of commercial identification systems such as API 20NE and VITEK 2 to identify Ochrobactrum species, showed that commercial kits were not always reliable for genus and species identification. Previous studies reporting the predominant role of O. anthropi in human disease by using non-discriminatory methods and/or before the discovery of other Ochrobactrum species suggested that some infections associated with O. anthropi in the literature should be revised. Further phenotypic features and genotyping methods (ex. recA-based analysis [29]) should be considered for more reliable identification of Ochrobactrum to the species level.

Most Ochrobactrum species are resistant to most β-lactams and sensitive to carbapenem, ciprofloxacin, trimethoprim/sulfamethoxazole or aminoglycoside (Table 3) [30]. Hence, empirical treatment with carbapenem, quinolone, cotrimoxazole and aminoglycoside is feasible. Ochrobactrum exhibited resistance to β-lactam antibacterial agents due to production of an inducible and chromosomally encoded Amp-C β-lactamase [2]. The β-lactamase characterized from O. anthropi was named OCH-1 (gene, blaOCH-1) [31]. Alonso et al. found the blaOCH gene in non-O. anthropi species with gene heterogeneity from food animals [32]. The isolated species identified by 16S rDNA sequencing and MALDI-TOF MS included O. intermedium and O. tritici. However, there is limited data regarding antibiotic resistance genes in non-antropi Ochrobactrum species from humans.

A new blaOXA, OXA-919, was found in our isolate and confers resistance to broad-spectrum β-lactam antibiotics. The emergence of OXA enzymes in recent years has caused huge difficulty in treating gram-negative infections. Some intrinsic OXAs have been identified in Acinetobacter species [33]. OXA-51-like β-lactamases are intrinsic to Acinetobacter baumannii [34] and may cause carbapenem resistance. OXA-134a is universal in Acinetobacter lwofii [35] and may have the potential to cause β-lactam resistance when transferred to other species. We analysed seven O. pseudogrignonense genomes and found all O. pseudogrignonense isolates harboured blaOXA-919 genes. Further investigation identified blaOXA-919 genes in several other Ochrobactrum species. Ochrobactrum may be a reservoir of OXA-919. O. pseudogrignonense is an emerging pathogen in immunodeficient and immunocompetent patients. Clinical isolates exhibit wide-spectrum β-lactam resistance. Whole genome sequencing shows that Class B, C and D β-lactamases are present in the SHIN genome. A new subgroup of OXA, OXA-919, is identified. O. pseudogrignonense may be a reservoir of multiple β-lactamases, and the impact on antibiotic resistance transfer needs further study.

Funding information
Y.T.H. was supported in part by the Ministry of Science and Technology (109-2221-E-194-038-MY3). F.Y.L. was supported in part by the Ministry of Science and Technology (109-2314-B-075A-009) and Taichung Veterans General Hospital (TCVGH-1103901C, TCVGH-1103901D, TCVGH-NK1109004).

Acknowledgements
We would like to thank Dr Lee Pan from Tokyo.

Author contributions
S.S., Y.H., J.C., Y.H. and P.L., were involved in the investigation; Y.H., J.C., C.L. and Y.M., performed the formal analysis; C.L., Y.H. and P.L.,
performed the validation; C.L., Y.M., Y.H. and P.L., were involved in the funding acquisition and conceptualization of the study; S.L., drafted the manuscript; S.L., Y.H. and P.L., revised the manuscript.

Conflicts of interest
The authors declare that there are no conflicts of interest.

Ethical statement
The study was approved by the Ethics Committees of Taichung Veterans General Hospital (CE20004B). Written informed consent for publication of their clinical details was obtained from the patient.

References
1. Ryan MP, Pembroke JT. The genus ochrobactrum as major opportunistic pathogens. In: Microorganisms, Vol. 8. 2016. 2020. p. 1797.
2. Higgins CS, Avison MB, Jamieson L, Simm AM, Bennett PM, et al. Characterization, cloning and sequence analysis of the inducible Ochrobactrum anthropi AmpC beta-lactamase. J Antimicrob Chemother 2001;47:745–754.
3. Kampfer P, Scholz HC, Huber B, Falsen E, Busse HJ. Ochrobactrum haematophilum sp. nov. and Ochrobactrum pseudogrognonense sp. nov., isolated from human clinical specimens. Int J Syst Evol Microbiol 2007;57:2513–2518.
4. Kettaneh A, Weill FX, Poilane I, Fain O, Thomas M, et al. Septic shock caused by Ochrobactrum anthropi in an otherwise healthy host. J Clin Microbiol 2003;41:1339–1341.
5. Wu Z, Peng W, He X, Wang B, Ban G, et al. Mushroom tumor: a new disease on Flammulina velutipes caused by Ochrobactrum pseudogrognonense. FEMS Microbiol Lett 2016;363:fnw226.
6. Cho HW, Byun JH, Kim D, Lee H, Yong D, et al. The first case of Ochrobactrum pseudogrognonense bacteremia in Korea. Ann Lab Med 2020;40:331–333.
7. Teysier C, Marchandin H, Jean-Pierre H, Diego I, Darbas H, et al. Molecular and phenotypic features for identification of the opportunistic pathogens Ochrobactrum spp. J Med Microbiol 2005;54:945–953.
8. Mrozek S, Dupuy M, Hoarau L, Lourtet J, Martin-Blondel G, et al. Brain empyema due to Ochrobactrum anthropi. Med Mal Infect 2014;44:128–129.
9. Chiu LO, Wang W. A case of unusual Gram-negative bacilli septic arthritis in an immunocompetent patient. Singapore Med J 2013;54:e164–8.
10. Gigi R, Flusser G, Kadar A, Salai M, Elias S. Ochrobactrum anthropi caused Osteomyelitis in the foot mimicking a bone tumor. J Foot Ankle Surg 2017;56:851–853.
11. Christenson JC, Pavia AT, Seskin K, Brockmeyer D, Korgenski EK, et al. Meningitis due to Ochrobactrum anthropi: an emerging nosocomial pathogen. A report of 3 cases. Pediatr Neurosurg 1997;27:218–221.
12. Mattos FB, Saraiva FP, Angotti-Neto H, Passos AF. Outbreak of Ochrobactrum anthopli endophthalmitis following cataract surgery. J Hosp Infect 2013;83:357–360.
13. Haviari S, Cassier P, Dananche C, Hulin M, Dauwalder O, et al. Outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi Infections after Prostate Biopsies, France, 2014. Emerg Infect Dis 2016;22:1412–1419.
14. Romero Gomez MP, Peinado Esteban AM, Sobrino Daza JA, Saez Nieto JA, Alvarez D, et al. Prosthetic mitral valve endocarditis due to Ochrobactrum anthropi: case report. J Clin Microbiol 2004;42:3371–3373.
15. Ozedmir D, Soy pracaci Z, Sahin I, Bick Z, Sencan I. Ochrobactrum anthropi endocarditis and septic shock in a patient with no prosthetic valve or rheumatic heart disease: case report and review of the literature. Jpn J Infect Dis 2006;59:264–265.
16. Ashraf F. 2016. A case of Ochrobactrum anthropi-induced septic shock and infective endocarditis. R I Med J 2013;99:27–28.
17. Sepe V, Esposito P, Sacco L, Ceci A, Magrassi A, et al. Peritonitis in type 2 diabetes mellitus due to Ochrobactrum anthropi complicating automated peritoneal dialysis. Acta Diabetol 2010;47:341–344.
18. YW, Peck KR. Biliary sepsis caused by Ochrobactrum anthropi. Jpn J Infect Dis 2010;63:444–446.
19. Song S, Ahn JK, Lee GH, Park YG. An epidemic of chronic pseudophakic endophthalmitis due to Ochrobactrum anthropi: clinical findings and management of nine consecutive cases. Ocul Immunol Inflamm 2007;15:429–434.
20. Gasmiyar H, Hoffman MA, Simonsen KA. Late-onset Ochrobactrum anthropi sepsis in a preterm neonate with congenital urinary tract abnormalities. J Perinatol 2014;34:489–491.
21. Cieslak TJ, Drabick CJ, Robb ML. Pyogenic infections due to Ochrobactrum anthropi. Clin Infect Dis 1996;22:845–847.
22. Appelbaum PC, Campbell DB. Pancreatic abscess associated with Achromobacter group Vd biovar 1. J Clin Microbiol 1980;12:282–283.
23. Naik C, Kulkarni H, Darabi A, Bhant N. Ochrobactrum anthropi: a rare cause of pneumonia. J Infect Chemother 2013;19:162–165.
24. Moller LV, Arends JP, Harmsen HJ, Talens A, Terpstra P, et al. Ochrobactrum intermedium infection after liver transplantation. J Clin Microbiol 1999;37:241–244.
25. Dharne MS, Misra SP, Misra V, Dwivedi M, Patole MS, et al. Isolation of urease-positive Ochrobactrum intermedium in the stomach of a non-ulcer dyspeptic patient from north India. J Microbiol Immunol Infect 2008;41:183–186.
26. Vaidya SA, Citron DM, Fine MB, Murakami G, Goldstein EJ. Pelvic abscess due to Ochrobactrum intermedium [corrected] in an immunocompetent host: case report and review of the literature. J Clin Microbiol 2006;44:1184–1186.
27. Vila A, Pagella H, Vera Bello G, Vicente A. Brucella suis bacteremia misidentified as Ochrobactrum anthropi by the VITEK 2 system. J Infect Dev Ctries 2016;10:432–436.
28. Poonawala H, Marrs Conner T, Peaper DR. Closing the brief case: Misidentification of Brucella melitensis as Ochrobactrum anthropi by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF ms). J Clin Microbiol 2018;56.
29. Scholz HC, Tomasos H, Al Dahouk S, Witte A, Schloter M, et al. Genotyping of Ochrobactrum anthropi by recA-based comparative sequence, PCR-RFLP, and 16S rRNA gene analysis. FEMS Microbiol Lett 2006;257:7–16.
30. Thoma B, Straube E, Scholz HC, Al Dahouk S, Zoller L, et al. Identification and antimicrobial susceptibilities of Ochrobactrum spp. Int J Med Microbiol 2009;299:209–220.
31. Nadjar D, Labia R, Cerceau C, Bizet C, Philippion A, et al. Molecular characterization of chromosomal class C beta-lactamase and its regulatory gene in Ochrobactrum anthropi. Antimicrob Agents Chemother 2001;45:2324–2330.
32. Alonso CA, Kwabugye YA, Anyanwu MU, Torres C, Chah KF. Diversity of Ochrobactrum species in food animals, antibiotic resistance phenotypes and polymorphisms in the blaoCHG gene. FEMS Microbiol Lett 2017;364.
33. Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006;57:1–3.
34. Heritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, et al. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:1474–1479.
35. Figueiredo S, Poirel L, Seifert H, Mugnier P, Benhamou D, et al. OXA-134, a naturally occurring carbapenem-hydrolyzing class D beta-lactamase from Acinetobacter Iwoffii. Antimicrob Agents Chemother 2010;54:5372–5375.
36. Hong JS, Kim JO, Kim JO, Hong JS, Jeong SH, et al. First case report of human infection with Ochrobactrum trichici causing bacteremia and cholecystitis. Ann Lab Med 2016;36:278–280.
37.Apisarnthanarak A, Kiratsins P, Mundy LM. Evaluation of Ochrobactrum intermedium bacteria in a patient with bladder cancer. Diagn Microbiol Infect Dis 2005;53:153–155.
38. Cieslak TJ, Drabick CJ, Robb ML. Pyogenic infections due to Ochrobactrum anthropi. Clin Infect Dis 1996;22:845–847.